Perigo updated its 2026 outlook after agreeing to divest infant formula, with core reported net sales expected to decline 2.5 to 3.6 percent amid cautious retailer inventories and continued European softness.
PRGO · PERRIGO Co plc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Perrigo’s third-quarter net sales fell $54.7 million, or 5.2%, while operating income declined $49.5 million, or 68.2%; the company also agreed to sell its Infant Formula business to MeridianMade for up to $175 million.
Perrigo Company plc reported Core adjusted diluted EPS of $0.61, down 9.0%, and agreed to divest Infant Formula for up to $175 million. The company expects a $275.0 million to $375.0 million impairment loss during the fourth quarter of 2026.
Perrigo entered a definitive agreement for MeridianMade to acquire its Infant Formula business for total consideration of up to $175 million, including $40 million cash at closing and up to $135 million in contingent payments. Closing is expected in the first half of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Perrigo reported Q2 sales declines (Core net sales down 3.1%) and lower adjusted EPS, but reaffirmed its full-year 2026 outlook, completed the $359M Dermacosmetics divestiture to reduce debt, and continued gaining market share (50 bps in U.S. and Europe) despite soft category trends.
- + Reaffirmed full-year 2026 outlook despite weak quarter
- + Completed $359M Dermacosmetics divestiture with proceeds applied to debt reduction
- + Continued market share gains of 50 bps in both U.S. and Europe despite category declines
- + Infant Formula delivered 23% sales growth and ~$60M operating income improvement
- − Core net sales declined 3.1% and adjusted EPS fell 20.7% year-over-year
- − Core adjusted gross margin declined 250 bps and operating margin fell 160 bps
- − Earnings beat driven by one-time benefits not expected to recur
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Constant currency net sales non-GAAP | $1.02B | Three Months Ended June 27, 2026 | — |
| Core Adjusted Net Sales non-GAAP | $906.7M | Three Months Ended June 27, 2026 | — |
| Core Adjusted Operating Income non-GAAP | $117.6M | Three Months Ended June 27, 2026 | — |
| Infant Formula Organic net sales non-GAAP | $100.9M | Three Months Ended June 27, 2026 | — |
| Organic net sales non-GAAP | $1.02B | Three Months Ended June 27, 2026 | — |
| Self Care Organic net sales non-GAAP | $573.4M | Three Months Ended June 27, 2026 | — |
| Specialty Care Organic net sales non-GAAP | $226.4M | Three Months Ended June 27, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRGO
this stock
PERRIGO Co plc
|
$2.19B | +13.2% | -2.8% | — | 17.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$69.14B | +38.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$52.00B | +7.6% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.73B | +36.6% | +4.3% | 96.9 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 23
Perrigo’s third-quarter net sales fell $54.7 million, or 5.2%, while operating income declined $49.5 million, or 68.2%; the company also agreed to sell its Infant Formula business to MeridianMade for up to $175 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRGO | -6.4% | -2.5% | +37.8% | -0.1% | +13.2% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -4.0% | +2.2% | +40.7% | +3.0% | +5.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.